- Home
- IMKTA vs PVLA Comparison
IMKTA vs PVLA Comparison
Compare IMKTA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMKTA | PVLA |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMKTA | PVLA |
|---|---|---|
| Price | $88.99 | $121.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $171.87 |
| AVG Volume (30 Days) | 104.4K | ★ 202.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104,350.18 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.09 | $20.20 |
| 52 Week High | $95.62 | $151.18 |
Technical Indicators
Market Signals| Indicator | IMKTA | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 47.40 |
| Support Level | $86.93 | $108.99 |
| Resistance Level | $89.76 | $135.23 |
| Average True Range (ATR) | 2.30 | 6.38 |
| MACD | -0.40 | -0.88 |
| Stochastic Oscillator | 24.21 | 10.14 |
Price Performance
Historical ComparisonAbout IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.